- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03505073
Association Between Dietary Habits and Risk Factors for Atherosclerotic Cardiovascular Diseases in Assiut Governorate
Study Overview
Status
Conditions
Detailed Description
Atherosclerotic cardiovascular diseases (ASCVD) has become the largest single cause of death worldwide. It is responsible for an estimated 17 million deaths and led to 151 million disability-adjusted life years (DALYs) lost (~30.0% of all deaths and 14.0% of all DALYs lost).1 Further, by 2020, 32.0% of the world population deaths will be caused by ASCVD and by 2030; it's expected to be responsible for 33.0% of all deaths (24.2 million).2 Most of atherosclerotic cardiovascular disease events nowadays are taking place in low- and middle-income countries with 80% of the burden occurring in these countries.3
In Egypt, since 1990, ASCVD related mortality was increased over three folds; to be responsible for over 40% of deaths compared with 12% reported two decades earlier.4 Egypt was categorized as a "very-high-risk country for ASCVD" (according to 2016 ESC Guidelines on cardiovascular disease prevention in clinical practice).5 According to (WHO 2014), ASCVD related mortality in Egypt has been increased to account for 46% of total deaths.
Multiple risk factors are attributed to causing ASCVD. These risk factors fall into the categories of either nonmodifiable or modifiable risk factors.6 Nonmodifiable risk factors consist of those conditions that a person cannot alter, including age, heredity, ethnicity and type 1 diabetes.
Whereas modifiable risk factors are conditions that can be altered by making certain lifestyle changes.
In 2003, the Canadian Heart and Stroke Foundation identified nine major modifiable risk factors for ASCVD, namely, tobacco smoking, alcohol abuse, physical inactivity, unhealthy dietary habits, obesity, high BP, high concentrations of dietary fat and blood lipids, and high blood glucose concentrations.7 Sudden stress, frequent migraine and the use of oral contraceptives have also been identified as risk factors for the increased incidence of coronary disease and stroke.8,9 The Egyptian National Hypertension Project (NHP)10,11 was conducted between year 1991 and 1993 in six Egyptian governorates to define the prevalence of ASCVD risk factors in adult Egyptians. The project documented an extremely high prevalence and prominent clustering of ASCVD risk factors in adult men and women particularly obesity.
Since that time, and despite the increasing ASCVD related morbidity and mortality in our Egyptian society, as mentioned before, there's no recent studies (up to our knowledge) was conducted to determine the risk factors associated to ASCVD.
This study overall aim is to systematically explore and investigate the association between dietary habits and risk factors for atherosclerotic cardiovascular diseases in Assiut governorate.
Study Type
Enrollment (Anticipated)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
- Inclusion criteria: Patients: male or female, aged ≥ 18 years and confirmed to have ASCVD, attending on the outpatient clinics or admitted in Inpatients Ward or ICU of Assiut university Heart Hospital and Assiut Health Insurance Hospital during the study period.
- Exclusion criteria: Patients: aged < 18 years and unconscious patients will be excluded from the study group.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Detecting the association between dietary habits and risk factors for atherosclerotic cardiovascular diseases in Assiut governorate.
Time Frame: 10 months
|
The study's overall aim is to systematically explore and investigate the association between dietary habits and risk factors for atherosclerotic cardiovascular diseases in Assiut governorate.
|
10 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10256
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atherosclerotic Cardiovascular Disease
-
Novartis PharmaceuticalsRecruitingAtherosclerotic Cardiovascular Disease (ASCVD)China, United States, Italy, Taiwan, France, United Kingdom, Hong Kong, Germany, Spain, Netherlands, Puerto Rico
-
Novartis PharmaceuticalsAvailableAtherosclerotic Cardiovascular Disease, ASCVD
-
Hospital do CoracaoRecruitingAtherothrombotic Diseases | Atherosclerotic Cardiovascular Disease (ASCVD)Brazil
-
Eli Lilly and CompanyActive, not recruitingElevated Lp(a) | Atherosclerotic Cardiovascular Disease (ASCVD)United States, France, Spain, Israel, China, Netherlands, Belgium, Austria, Taiwan, United Kingdom, Greece, Denmark, Italy, Japan, Hungary, Poland, Germany, Romania, Argentina, Brazil, Mexico, Czechia, Australia, Puerto Rico, India, Slovakia and more
-
Henan Province Clinical Research Center for Cardiovascular...Not yet recruitingAtherosclerotic Cardiovascular DiseasesChina
-
Novartis PharmaceuticalsCompletedElevated Lp(a) and Established Atherosclerotic Cardiovascular DiseaseUnited States, Puerto Rico
-
Advanced Education & Research CenterUniversity of Karachi; Pakistan Cardiac Society (Heart House)RecruitingAtherosclerotic Cardiovascular Diseases (ASCVD)Pakistan
-
Pauls Stradins Clinical University HospitalActive, not recruitingAtherosclerotic Cardiovascular DiseaseLatvia
-
SanofiCompletedAtherosclerotic Cardiovascular Disease Without Prior Ischemic EventsUnited States
-
Novartis PharmaceuticalsCompletedAtherosclerotic Cardiovascular Disease | Atherosclerotic Cardiovascular Disease Risk Equivelents | Elevated Low Density Lipoprotein CholesterolUnited Kingdom